Ordspono Will Be Regeneron’s First Independent European Launch

Ordspono, a bispecific antibody newly approved in the EU to treat follicular lymphoma and diffuse large B-cell lymphoma, joins Libtayo in Regeneron’s growing oncology portfolio.

Regeneron's first bispecific antibody was approved in Europe • Source: Shutterstock

More from New Products

More from Scrip